Document is current
Any future updates will be listed below
-
Authors
Clouthier, Derek L.
Lien, Scott C.
Yang, S. Y. Cindy
Nguyen, Linh T.
Manem, Venkata S. K.
Gray, Diana
Ryczko, Michael
Razak, Albiruni R. A.
Lewin, Jeremy
Lheureux, Stephanie
Colombo, Ilaria
Bedard, Philippe L.
Cescon, David
Spreafico, Anna
Butler, Marcus O.
Hansen, Aaron R.
Jang, Raymond W.
Ghai, Sangeet
Weinreb, Ilan
Sotov, Valentin
Gadalla, Ramy
Noamani, Babak
Guo, Mengdi
Elston, Sawako
Giesler, Amanda
Hakgor, Sevan
Jiang, Haiyan
McGaha, Tracy
Brooks, David G.
Haibe-Kains, Benjamin
Pugh, Trevor J.
Ohashi, Pamela S.
Siu, Lillian L.
-
Funding
Funding for this research was provided by:
Princess Margaret Cancer Foundation
Terry Fox Research Institute
- License Information
-
More Information
Article History
Received: 18 December 2018
Accepted: 20 February 2019
First Online: 13 March 2019
Ethics approval and consent to participate
: Participants provided informed consent to participate in the study, which was approved by the Research Ethics Board at the Princess Margaret Cancer Centre and registered at, and is being conducted in accordance with the principles of Good Clinical Practice, the provisions of the Declaration of Helsinki, and other applicable local regulations.
: Not applicable.
: After the data cut-off date, DLC became an employee of Ipsen and is a current employee of Pfizer. ARH has served as a consultant advisor for Merck. RJ received honorarium from Ipsen, and is a site PI for Merck, BBI, Astra Zeneca, Eli Lilly, Novartis clinical trials. PSO has received compensation as a consultant advisor to Venus, Symphogen, and Providence. LLS has received compensation as a consultant advisor for AstraZeneca/Medimmune, Merck, MorphoSys, Pfizer and Symphogen and is a site PI for Merck clinical trials.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
